The unclear pathogenesis of scleroderma vascular lesions makes treatment of Raynaud's phenomenon (RP) in Systemic Sclerosis (SSc) patients very difficult and a new effective treatment is requested. Recently, a powerful antioxidant agent, the N-acetylcysteine (NAC) has been shown to decrease the frequency and severity of RP in SSc patients. Subsequently, using functional infrared imaging, we showed that a single 1hour NAC infusion in these patients caused a significant increase of skin temperature. The aim of this study was to demonstrate the efficacy of long term therapy with NAC in an open, clinical trial evaluating clinical, instrumental and laboratory parameters. Patients started the treatment receiving for two years, from October to May, intravenous NAC infusions of 15 mg/kg per hour each, for 5 consecutive hours, every two weeks. Before and after each infusion, patients underwent both Laser Doppler perfusion Imaging (LDPI) for the evaluation ofthe digital perfusion and a blood test to ascertain the plasma adrenomedullin (AM) levels. The NAC infusion increased global hands perfusion and induced a significant decreasing of plasma AM concentrations. Side effects were negligible, easy to control and reversible. Reduction of frequency and severity of RP attacks was recorded. In conclusion, NAC seems to act as an effective vasodilatator in the treatment of RP secondary to SSc and, in addition, it induced significant changes in plasma levels of AM, a potent vasodilator endothelial-derived peptide.
The antioxidant activity ofNAC appears to be related to at least two mechanisms i.e. the nucleophilic properties of the molecule accounting for its free radicals scavenger activity and the capacity to support gluthatione synthesis. SSc lung macrophages express high levels of nitric oxide synthase, produce a significant quantity of peroxynitrite and NAC administration reduces peroxynitrite production (3) .
Thiol supplementation with NAC improves human and peripheral endothelium-dependent vasodilatation. NAC increases NO-mediated effects in the fetoplacental circulation in preeclamptic placentas (4) and a single infusion ofNAC reduces postraumatic microvascular dysfunction following closed soft tissue trauma in rats, attenuates both leukocyte adherence and tissue infiltration (5) .
A treatment with a powerful antioxidant agent such as NAC should ameliorate the ROS-induced damage. Recently a single 5-day infusion ofNAC in hospitalised SSc patients decreased the frequency and the severity of RP attacks and the number of active ulcers (6) . Subsequently, using functional infrared imaging, we showed that a single I-hour NAC infusion in SSc patients caused a significant increase of face and hands temperature (7) .
Adrenomedullin (AM) is a 52 amino-acid vasorelaxant peptide (8) synthesized by many mammallian tissues including the adrenal medulla, endothelial and vascular smooth muscle cells (8) (9) . Several studies suggested that TNF, IL-l,and lipopolysaccaride potently stimulated AM production (10) . The role ofNAC in the regulation of several proinflammatory mediators and endothelial cell activity has induced us to evaluate the effects ofNAC therapy on peripheral perfusion and on plasma AM levels.
MATERIALS AND METHODS
Patients 26 patients suffering for RP secondary to diffuse or limited SSc were recruited from among outpatients. They were selected from among those who could not undergo treatment with calcium channel antagonists or intravenous infusions of prostanoids because of their side effects; 4 were male and 22 female. Patient age range was 25-68 years (43.9 ± 12.8). SSc was diagnosed according to the criteria of the American College of Rheumatology: 14 patients had limited sclerosis, 12 patients had diffuse sclerosis. Patient disease ranking was obtained evaluating: autoimmunity, cutaneous score, Raynaud's score and hands perfusion.
Patients were enrolled only if they met the criterion of a minimum of7 attacks ofRP per week documented by the patient diary and/or one or more cutaneous ischemic lesions of fingers. Patients were excluded if they met any of the following conditions: pregnancy, a history of bronchial asthma, hypertension treated with calciumchannel blockers or ACE inhibitors, sympathectomy of the upper limb performed within 12 months from the beginning of the study.All medications, except omeprazol, were discontinued starting 14 days before the first day of infusion. All patients gave written informed consent and ethical permission was obtained from the appropriate local ethical committees.
The baseline characteristic of the 26 patients enrolled in the study are shown in Table 1 .Two patients decided to move to a different medical center and interrupted the treatment, at the second and at the twelfth month, respectively; one started the treatment after eight months from the start of the study. 
Study medication and administration

Assessment ofefficacy
To assess the effectiveness of the NAC long term treatment in patients with RP secondary to SSc, we used both clinical and instrumental parameters. Laser Doppler Perfusion Imaging (LDPI) was used to record possible changes in cutaneous perfusion. Plasma AM concentrations were measured with a specific-radio-immunoassay.
Each patient subjectively reported -on a personal diarywhen each RP attack occurred. Patients were also providedand instructed on use -with a 0-10 Visual-Analog Scale (VAS)to report the attack severity score.They were instructed to assign O-scoreto the absence ofattack, and 10-score to the most severe one in terms of pain and impact on daily activities.
Arithmetic means for individual diary scores and for a 16 months period were computed.
Digital ulcers -marginal lesions ofischemic origin spread from epidermis and dermis destruction -were counted.
Laser Doppler Perfusion Imaging (LDPI)
Laser Doppler Perfusion Imaging (LDPI) is a recent technique for assessing microcirculatory flow. Since no physical contact with the tissue is necessary, and no dyes or tracer elements are used, the evaluation is not invasive and allows imaging of the perfusion (11) .
LDPI investigation consisted in recording the digital perfusion at the basal state and after the infusion, 30 minutes before and 30 minutes after the infusion. LDPI was performed in a quiet room with a stable and controlled temperature (21 ± 0.5 "C) and humidity (50-60%). A lowenergy 670 nm Lisca Laser Doppler Perfusion Imager (Lisca PIM II) was used.
Quantitative LDPI parameters considered were: Global mean, minimal and maximal perfusion of the hands;
Proximal-distal gradient perfusion -defined as difference between mean perfusions of the dorsum ofthe hand of the terminal phalanx.
To get a normal control baseline, we enrolled 20 normal volunteers that underwent LDPI measurements, at resting conditions The measurements were performed in the environment and with the same experimental conditions, as for the patients. Age and characteristics of the normal volunteers were matched to those of the patients.
Plasma adrenomedullin concentrations AM was measured with a specific radioimmunoassay (RIA, PHOENIX PHARM; Inc. Mountain View, CA; USA) as reported (12) . The anti-AM antibody cross-reacts at 100% with human AM-( 1-52) but not with rat AM-( 1-50), human amilin, human calcitonin gene related peptide, endothelin-1, a. atrial natriuretic peptide-( 1-28),~atrial natriuretic peptide-(32) or catrial natriuretic peptide- (22) . The effective range of the standard curve was between 2 and 200 pg of human AM per assay tube. Inter-assay variation was 12% and intraassay variation was 5%. All assays were performed in duplicate. Concentrations of AM were expressed as pg/ml. In our laboratory mean plasma AM normal values are 10.4 ± 2.4 pg/ml (range 3-13 pg/ml).
Tolerability and safety
Any possible adverse effect was recorded during the NAC infusion and reported by the patients at the followup visits. Blood pressure and cardiac frequency were measured during the infusion period and at each visit. Haematologic parameters considered so far were: haemoglobin, erythrocyte count, leucocytes count and platelet count. Serum chemistry included sodium, potassium, calcium, creatinine, alanine transaminase (ALT) and aspartate transaminase (AST).
Statistical Analysis
All continuous variables are shown as mean + SD.
Data were analyzed throughout standard Student's test; the statistical significance of which was fixed at p < 0.05.
RESULTS
Frequency ofRaynaud's phenomenon attacks
The frequency ofRP attacks was estimated from the total number of attacks recorded by the patients in their personal diary. In the two weeks, the mean weekly frequency of RP attacks before treatment was 23.2 ± 14.6. In the two weeks following the first treatment (from day 5 to day 19), mean weekly frequency ofRP attacks decreased to (13.2 ± 7.6), i.e. 43.1 % less than the basal value. After the second treatment (from day 20 to day 33) the mean weekly frequency of RP attacks still continued to decrease, reaching 11.5 ± 6.8, i.e. 50.4% less than the basal value. Mean weekly frequency of RP attacks along the last four weeks of follow up (starting from day 34) decreased to (10.8 ± 6.2), i.e. 53.4% less than the basal value. Table II summarizes and reports such results.
Severity ofRaynaud 's Phenomenon
The severity of digital pain during each attack of RP was estimated using a IO-point scoring VAS. Patients marked the score on the diary cards. The daily mean RP severity score at baseline was (5,3 ± 1,7). The mean percentage of severity score, after treatment with NAC, was significantly reduced (p < 0.05) when compared to baseline values (41.5%, 43.4% and 39.6% at days 5-19, 20-33, and 34-61, respectively).
Evaluation ofcutaneous microcirculation
Data obtained by evaluation of digital perfusion with LDPI are summarized in Table III . 375 matching were done between Laser Doppler images before and after NAC infusion. LDPI output data are reported as proportional to an electronic signal (voltage V). Therefore, LDPI data hereby reported are to be intended as arbitrary perfusion units.
Mean global perfusion of hands changed from (0.79 ± 0.21) V to (0.99 ± 0.24) V; minimal perfusion changed from (0.16 ± 0.005) V to (0.27 ± 0.006) V; and maximal perfusion from (2.47± 0.04) V to (2.87± 0.04) V. In normal volunteers, mean perfusion values were (0.97 ± 0.1) V, minimal perfusion values were (0.23 ± 0.09) V, and maximal perfusion values were (3.085 ± 0.9) V (Fig. 1 ). 375 confrontations (80.8% of the population) demonstrated a positive difference post-pre infusion in all of the three parameters considered: mean, minimal and maximal perfusion. Only 18.4% of the differences were negative. All of the cases of negative difference belonged to a group of patients, whose basal perfusion was higher than the mean basal perfusion value of the whole sample. Moreover, the increasing rate of perfusion values after NAC treatment seems to be correlated to the pre-infusion perfusion values: the lower the preinfusion perfusion values, the higher the increasing of perfusion. This trend is described in Fig. 2 .
Evaluation ofplasma Adrenomedullin (AM) concentrations
We measured plasma AM levels in patients with SSc before and after NAC treatment. In this study we revealed that plasma AM concentrations were increased in SSc patients (30.4 ± 18 pg/ml) compared to control values (10.4 ± 2.4 pg/ml) (p < 0.05). Plasma AM concentrations have changed from pre-infusion mean value of 30.4 ± 18 pg/ml (p<0,05) to a post-infusion mean value of 20.4 ± 6 pg/ml (Fig. 3 ).
Adverse events
The infusion of NAC was well tolerated and no relevant side effects lead to discontinuation of treatment or to withdrawal from the study. The most frequent minor adverse events were flushing and headache and, less frequently, nausea/vomiting, epigastric pain and arthralgia. No significant effects were noticed on blood pressure or heart rate during NAC treatment. Four patients developed a transient arterial hypertension and four a mild urticaria. All the minor adverse events were reversible and disappeared at the end of infusion.
DISCUSSION
Previous observations demonstrated that intravenous NAC is useful in the treatment of RP secondary to SSc (6-7). By using LDPI, images and quantitative values of the increasing perfusion, after a 5 hours NAC infusion were recorded; moreover, a long term NAC treatment of SSc outpatients was tested with no relevant side-effects, showing, after a two year periodic therapy, the disappearance of newly formed digital ulcers.
Laser Doppler is a new technique that quantifies microcirculatory flow in patients with primary RP and SSc. In respect to nailfold capillaroscopy and conventional laser Doppler flowmetry systems, LDPI allows the simultaneous assessment of all ten fingers and takes into account any interdigital perfusion variation. LDPI builds up a flux map by scanning the probe laser. These maps show the inherent nonhomogeneneity ofthe microcirculation and permit to average over regions of interest, such as the dorsum of the hand or the fingertips. Moreover LDPI images cannot alter blood flow because there is no contact with the fingers. Even under standard conditions of room temperature and humidity, the temperature of individual fingers may be widely different from patient to patient and from time to time. Thus, if using only capillaroscopy, the selection of worst or least affected fingers will give an unreliable assessment of therapy.
In our patients, LDPI demonstrates the formal evidence that NAC infusion increases the mean values ofhand perfusion, acting as a vasodilator. The physiopathological basis of the effects of NAC are still unclear (13) (14) (15) . It can be hypothesized that NAC antioxidant properties inhibit the release of free radical species from circulating cells (16) . The replacing endogenous antioxidant mechanism, such as the GH-redox pathway, and that NAC could ameliorate Raynaud's attacks through its effects on microcirculatory blood flow and tissue oxygenation.
Vasodilatation is mediated by NAC activation of guanylate cyclase, the enzyme responsible for vasorelaxation, and by the generation of sulphydryl groups which are required both for the relaxation of vascular smooth muscle and for the full activity of the endothelium-derived relaxing factor through the generation of nitroso-thiols. The observation that NAC does not potentiate endothelium-dependent vasodilatation in normal volunteers in whom oxidative stress is low (17) and instead it seems efficient in SSc patients is very interesting.
It seems that some of the clinical features of SSc are due to an excessive oxidative stress; pathological features of SSc, such as endothelial cell dysfunction and fibroblast proliferation, are probably induced by reactive oxygen species; for this direct and indirect evidence of enhanced oxidative stress in SSc patients, the use of antioxidant therapy in SSc disease is attractive.
Human AM consists of 52 amino-acids which show partial sequence homology with the potent vasodilatator calcitonin gene-related peptide (CGRP) (8) . It was first isolated from pheochromocytoma and the adrenal medulla (8) , but is also formed in other tissues and organs (9) . AM gene is also expressed in vascular endothelial cells and vascular smooth cells (9) and secretion of AM was examined in isolated and/or cultured endothelial cells, vascular smooth muscle cells and cardiomiocytes. AM production is up-regulated by oxidative stress, proinflammatory cytokines such as TNFa. and IL-1, angiotensin II and endothelin-1 (10, (18) (19) AM is present in human plasma, suggesting that it may be a circulating hormone (20) . Although its physiological role is unclear, animal and human studies have shown that it lowers systemic vascular resistance and that it is natriuretic and diuretic (21) . Besides its potent vasodilatatory action, AM might play an important role in the regulation of inflammatory processes (22) . We measured plasma AM levels in patients with SSc and the results confirmed and extended our and other data on behavior of plasma AM in patients with RP (23) and in patients with SSc (24) (25) (26) .
The mechanism by which plasma AM levels increase in patients with SSc remains unknown. Several tissues including vessels secrete AM, and elevated AM could conceivably be caused by secretion from vascular cells in general. Another noteworthy aspect of AM behavior in SSc concerns the relationship between this peptide and endothelin-1 (ET-1) secretion. In fact, patients with SSc have higher plasma ET-11evels than controls (27) . Indeed, whereas AM possesses action (28) powerful vasodilatatory (23) an anti-proliferative effect (29), ET-1 induces an intensive vasoconstriction (30) and proliferation. Moreover, ifNAC reduces in vitro cellular production ofpro-inflammatory mediators (e.g. TNF-a., IL-1) (31-33) and these cytokines induce plasma AM synthesis and secretion, NAC treatment could induce plasma AM reduction.
The results presented in this study are in agreement with that hypothesis, the AM plasma levels markedly reduced after infusion ofNAC: at higher pre-infusion plasma AM values, we find higher decrease ofplasma AM values. Therefore, we could hypothesize that AM overproduction in SSc patients may have a compensatory effect in reducing ET-1 activity. Progressive reduction ofplasma AM concentrations in our patients with SSc during NAC treatment could be a parameter oftreatrnent efficacy; in fact vasodilatation NAC-induced could take to a generation of a negative feedback signal on AM secretion. As a consequence, plasma AM levels decrease.
In conclusion, the results of this study on intravenous NAC efficacy in SSc strongly encourage going further into a larger, double-blind, placebocontrolled study to determine the NAC role in the treatment of RP. At the present state, data from this study confirm the efficacy of NAC treatment for RP SSc patients, also in a long term administration without relevant side-effects, the increase in peripheral perfusion and the modulation of AM, an important endothelial mediator.
